Ranbaxy Laboratories, India’s largest pharmaceutical company, announced that the company has received the final approval from the US Food and Drug Administration (USFDA) to make and market Sumatriptan Succinate tablets in the country.

Sumatriptan Succinate tablets are used in treating migraine attacks.

While Ranbaxy got approval for 25 and 50 mg tablets of the drug, Aurobindo got the approval for 100 mg variants apart from 25 and 50 mg.

Mr. Bill Winter, Ranbaxy Laboratories Vice President, trade sales, North America, told that the company is delighted to receive this final approval for Sumatriptan Succinate Tablets 25 mg and 50 mg in addition to the 100 mg that was previously sanctioned.

The US Food and Drug Administration (USFDA) found the Ranbaxy formulations to be bio-equivalent and have the similar therapeutic effect as that of GlaxoSmithKline’s patented drug Imitrex.

Shares of Ranbaxy Laboratories, on Tuesday, closed at Rs 277.10, up 6.17% or Rs 16.10. The total quantity of shares traded was 908,895 on the BSE.